Mark Sullivan

Mark Sullivan is a Venture Partner at Adjuvant Capital, where he leverages his extensive biotechnology expertise to evaluate and manage global health investments. His professional background spans 28 years in clinical drug development across the biotechnology, large pharmaceutical, contract services, and academic sectors, alongside 11 years serving in executive management, advisory, and board of directors roles. Sullivan has directed project leadership for five distinct biopharmaceutical products throughout his tenure in the life sciences industry. Notably, he led the Global Health Innovation Fund investment in the moxidectin program, which successfully secured FDA approval in June 2018. This significant regulatory milestone marked the first new medical treatment for onchocerciasis introduced to the market in over 20 years. Sullivan maintains a primary focus on advancing clinical development strategies and funding innovative global health technologies targeting neglected infectious diseases.